Prevalence of psychotropic drug use
Numerous studies have addressed the psychiatric diagnoses for which psychotropic medications are prescribed for children and adolescents (
9,
11); the frequency of prescriptions associated with outpatient, office-based visits (
11–
13); and, in particular, the increase in the number and percentage of children being treated with various classes and combinations of psychotropic drugs (
9,
11,
14–
17). These increases have been observed across various populations, including youths enrolled in Medicaid, youths in foster care, preschoolers, and adolescents (
13,
16,
18,
19).
An analysis of data from nearly 900,000 children and adolescents found a two- to threefold increase from 1987 to 1996 in the percentage of patients taking any psychotropic medication; 1996 rates ranged from 5.9% to 6.3% across three sites (
20). Using data from the National Ambulatory Care Survey (NAMCS), another study found that for adolescents age 14 to 18, the percentage of office visits that resulted in a psychopharmacological prescription increased from 3.4% in 1994–1995 to 8.3% in 2000–2001 (
13). The authors further noted that 10% of office visits for males in 2001 resulted in such prescriptions. Using more recent data from the NAMCS (1996–2007), Comer and colleagues (
11) reported that 8.8% of office-based visits for children age six to 17 involved a prescription for one of five types of psychotropic medications (medications for attention-deficit hyperactivity disorder [ADHD], antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics). In addition, Aparasu and Bhatara (
12) reported that 1% (approximately two million) of all office visits by children and adolescents in 2003–2004 involved prescriptions for antipsychotic medications, primarily second-generation antipsychotics, most frequently risperidone.
In regard to specific disorders, ADHD is one of the most common psychiatric disorders diagnosed among children and adolescents (
21). As Mayes and colleagues (
15) noted, as many as half of all youths treated at child psychiatry clinics have received an ADHD diagnosis. Comer and colleagues (
11) reported that 42.9% of visits by children and adolescents that involved a prescription for psychotropic medications were by youths with disruptive behavior diagnoses, including ADHD. Olfson and colleagues (
22) noted a fourfold increase in the likelihood of stimulant use among children between 1987 and 1996, and Zito and colleagues (
23) found that two-thirds of office visits for ADHD medication were with primary care providers. Consistent with these findings, Shatin and Drinkard (
9) reported that primary care providers prescribed approximately 70% of stimulants used by children and adolescents.
Depression and mood disorders are also relatively common among children and adolescents. Ma and colleagues (
24) noted that various sources have cited prevalence rates of 2% to 8%, the latter in adolescent populations. Olfson and colleagues (
22) reported an increase in antidepressant use among children and adolescents from .3% to 1.0% from 1987 to 1996, and Zito and colleagues (
20) documented prevalence rates from 1.7% to 2.1% in 1996. Others have also noted increases (
14,
25), particularly among adolescents, and Comer and colleagues (
11) found that 21.5% of office visits for psychotropic medications by children and adolescents were related to mood disorders.
In 2004, the U.S. Food and Drug Administration issued a black-box warning that antidepressants may increase the risk of suicidality among children and adolescents (
26). After the warning, researchers noted a decrease in use of antidepressants among children, nationally (
27) and in one state's Medicaid program (
28). This decrease was accompanied by a decrease in the diagnosis of depression among children (
28).
Antipsychotic medications are also prescribed to children and adolescents (
29), including second-generation antipsychotics (
29–
31). According to one report, prescription of such drugs to youths increased nearly 500% from 1993 to 2002 (
29). In addition, from 2000 to 2002, antipsychotics were involved in nearly one out of ten mental health office visits by children and adolescents and in over 18% of visits to psychiatrists (
30). The authors noted that “second-generation agents composed 92.3% of the antipsychotic medications prescribed in office-based practice to children and adolescents” (
30). Endocrine, metabolic, and other potential side effects have been noted with the use of second-generation antipsychotics (
30–
33), and at least one author has attempted to “provide a practical guide for the evaluation and management of antipsychotic-related adverse effects in this vulnerable population” and also noted that “the widespread use exceeds the database regarding efficacy as well as safety and tolerability in this population” (
34).
In the context of the complexities associated with the use of second-generation antipsychotics, the American Academy of Child and Adolescent Psychiatry (AACAP) has posted a recently approved practice parameter for use of these drugs with children and adolescents that provides guidelines for screening and assessment, dosing, and monitoring (
35). It also addresses risks, potential side effects, and safety issues related to these drugs and provides information about their efficacy and related research. The practice parameter includes the following caution: “While there is a growing body of evidence that has evaluated the use of atypical antipsychotics in youths, there remains a compelling need for methodologically rigorous trials assessing the efficacy and the acute and long-term safety of these drugs” (
35).
Not surprisingly, given the marked increase in psychotropic prescriptions, polypharmacy—or the simultaneous prescription of two or more psychotropic medications—is not uncommon (
11,
18), and there are indications that it is increasing (
11). In their recent review of polypharmacy among children and adolescents, Comer and colleagues (
11) reported that according to 2004–2007 data, 20.2% of office-based visits that involved a psychotropic medication “mention” included two different classes of medication; in the context of a diagnosed psychiatric disorder the percentage rose to 32.3%. Further, they found that antidepressants were the psychotropic medications most commonly prescribed and that drugs to treat ADHD were the second most frequently prescribed during visits in which multiple medications were prescribed. With regard to specific combinations, antidepressants are frequently prescribed with stimulants for children with ADHD; clonidine is another drug prescribed along with stimulants, as are antipsychotics (
18,
23). Antidepressants and antipsychotics are combined in a substantial proportion of instances of polypharmacy (
18), and some combinations also include mood stabilizers (
11).
All psychotropic medications for children must be prescribed with care and caution, and this is especially the case with polypharmacy. The AACAP has made it clear that currently there is “limited support” for coprescribing psychotropic medications and that a “clear rationale” is required for doing so (
36). Further, the AACAP has noted that before prescribing more than one medication, the provider must develop a plan both for the intervention and for supervising the intervention, must provide information and education to the child and family, must ensure assent from the youth and consent from the parent or guardian, and must conduct the medication trial according to AACAP guidelines.
Pediatric primary care providers and psychotropic medication
Studies examining numbers of patients and numbers of outpatient office visits have found that primary care providers prescribe most of the psychoactive medications used by children and adolescents (
8,
9,
11,
37). These findings are related largely to medications commonly prescribed for ADHD and depression. However, one study reported that more than three-quarters of office visits associated with prescriptions for anxiolytics, antipsychotics, and mood stabilizers for youths occurred with primary care providers, not psychiatrists (
8).
Although the substantial role that pediatric providers play in prescribing psychotropic medications may not initially appear to be problematic, several related findings raise concerns and suggest that too much may be expected of these providers when they do not have the benefit of extensive training in behavioral health or the support of behavioral health specialists. First, research suggests that these providers do not always identify the disorders that their patients have (
1,
7,
38). If the providers are not identifying these disorders, then it is unlikely that they are prescribing medications that may be beneficial to address the disorders or they may be prescribing medications that are not appropriate to a child's psychiatric diagnosis.
Second, pediatric primary care providers have reported substantial variations in their comfort level with diagnosing psychiatric disorders among children and with intervening with children who have various behavioral health problems; in general, they have reported greater comfort with problems such as ADHD, depression, and anxiety than with other disorders (
39–
42). Consequently, and as a recent study suggests, they may also be more comfortable prescribing stimulants and less comfortable prescribing second-generation antipsychotics and combinations of medications (Pidano AE, Honigfeld L, Bar-Halpern M, et al., unpublished manuscript, 2011). However, some pediatric primary care providers do prescribe classes of medications such as antipsychotics and coprescribe multiple psychotropics. In addition, although Harpaz-Rotem and Rosenheck (
37) stated that they found marked similarity in the prescribing practices of primary care providers and psychiatrists (for example, in dosage and types of medications), they also reported that retention rates beyond the first visit were higher for psychiatrists, which can be critical in terms of monitoring medication compliance and response. “One approach to improving retention among patients treated by primary care providers,” they suggested, “may thus be to promote collaborative models of care which coordinate the work of primary care providers and nonprescribing mental health professionals (i.e., clinical social workers and psychologists” (
37).
Lack of training is a third potential concern and may be one of the reasons for pediatric providers' limited comfort with identifying and diagnosing behavioral health disorders and managing children with them. Many pediatric primary care providers do not have extensive specialized training and may have no specialized training related to developmental and behavioral pediatrics (
39,
38).